Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Down Today?
By the Top Tier Newswire AI Desk · October 21, 2026 at 3:54 PM ET · reviewed against 32 wire stories
RAPPORT THERAPEUTICS Equity (RAPP) is down -15.20% in the latest session. Our newswire has captured 32 stories on RAPP across 14 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Rapport Therapeutics shares fell 15.20% to $24.91 on October 21, 2026. The decline followed the announcement of positive Phase 2 topline results for RAP-219 in acute bipolar mania, which met primary and secondary endpoints. Despite the clinical success, the stock sold off as analysts issued mixed price target adjustments and the stock printed fresh 52-week lows.
What Happened
Rapport Therapeutics reported that RAP-219 achieved a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale at Week 3 with a p-value of 0.045. The company stated these results set up FDA discussions and a path toward Phase 3 trials. Following the data release, Guggenheim raised its price target to $70 from $65. Jones Trading raised its target to $82 from $50. Conversely, Wells Fargo lowered its price target to $50 from $51, citing FOS risk. Raymond James increased its target to $86, while HC Wainwright & Co. maintained a $66 target. The stock had already declined 16.1% over the previous eight sessions, moving from $30.15 to $25.29 before today’s drop.
What The Data Shows
The stock opened at $28.41, a 3.3% gap down from the prior close of $29.37. It reached a session high of $29.91 at 9:30 AM ET before sliding to a session low of $24.69 at 10:30 AM ET. Volume reached 1.5 million shares, which is 3.9 times the three-month daily average. The company has a market cap of $1.4 billion and is unprofitable with a trailing twelve-month EPS of $3.05. The stock’s 52-week range is $23.75 to $52.93. On October 21, the stock printed 24 fresh 52-week lows. Recent insider activity includes nine sales totaling $7.0 million over the last 90 days, with no buys. CEO Ceesay Abraham sold shares on October 6 and September 23, while COO Cheryl Gault sold on September 30.
What To Watch
Analyst coverage remains active with 32 stories from 14 sources in the last 36 hours. Investors will monitor the company’s next steps in FDA discussions following the Phase 2 data. The stock’s beta of 1.22 suggests higher volatility relative to the broader market.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
RAPP · today's session (5-min) · -11.49% vs prior close · updated 8:42 PM ETAI sentiment, last 36h · averaged over 32 stories · 65/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
12h agoMarketChameleonBULLISH 74Product/PR
Rapport’s RAP-219 posts statistically significant Phase 2 bipolar mania wins, setting up FDA talks and a Phase 3 path
October 21, 2026
Rapport Therapeutics reported positive Phase 2 topline results for RAP-219 in acute bipolar mania, meeting primary and secondary endpoints with a 3.1-point placebo-adjusted improvement in YMRS at Week 3 (p=0.045) and a 0.4-point improvement in CGI-BP mania severity (p=0.024). The company said the drug was well tolerated with no serious adverse events during treatment, and it expects FDA discussions in Q1 2027 ahead of planned Phase 3 trial starts in the second half of 2027.
15h agoThe FlyBULLISH 64Analyst
Rapport Therapeutics price target raised to $70 from $65 at Guggenheim
Wells Fargo cuts Rapport Therapeutics price target on FOS risk
Wells Fargo cuts Rapport Therapeutics price target on FOS risk
1d agoSeeking AlphaBULLISH 58Product/PR
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update October 20, 2026 8:00 AM EDTCompany ParticipantsJulie...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →